• 1664 Citations
  • 25 h-Index
20072020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Britta Will is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

  • Publications

    The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation

    Adrianzen-Herrera, D., Choudhary, G., Gordon-Mitchell, S., Ramachandra, N., Bhagat, T. D., Zhang, H., Aluri, S., Shastri, A., Steidl, U. G., Will, B., Yang, W. L., Mahler, M., Eichenbaum, G., Guha, C. & Verma, A., 2020, (Accepted/In press) In : Leukemia and Lymphoma.

    Research output: Contribution to journalArticle

  • HIV portends a poor prognosis in myelodysplastic syndromes

    Kaner, J. D., Thibaud, S., Jasra, S., Wang, Y., Janakiram, M., Sharma, A., Sridharan, A., Elias, H., Polineni, R., Assal, A., Weiss, L., Braunschweig, I., Steidl, U., Pradhan, K., Shastri, A., Chaitowitz, M., Zingman, B., Will, B., Mantzaris, I. & Verma, A., Dec 6 2019, In : Leukemia and Lymphoma. 60, 14, p. 3529-3535 7 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Mechanisms and therapeutic prospects of thrombopoietin receptor agonists

    Bussel, J., Kulasekararaj, A., Cooper, N., Verma, A., Steidl, U., Semple, J. W. & Will, B., Oct 2019, In : Seminars in hematology. 56, 4, p. 262-278 17 p.

    Research output: Contribution to journalReview article

  • Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level

    Chen, J., Kao, Y. R., Sun, D., Todorova, T. I., Reynolds, D., Narayanagari, S. R., Montagna, C., Will, B., Verma, A. & Steidl, U., Jan 1 2019, In : Nature Medicine. 25, 1, p. 103-110 8 p.

    Research output: Contribution to journalLetter

  • 28 Scopus citations

    Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes

    Santini, V., Valcarcel, D., Platzbecker, U., Komrokji, R. S., Cleverly, A. L., Lahn, M. M., Janssen, J., Zhao, Y., Chiang, A., Giagounidis, A., Guba, S. C., Gueorguieva, I., Girvan, A. C., Da Silva Ferreira, M., Bhagat, T. D., Pradhan, K., Steidl, U., Sridharan, A., Will, B. & Verma, A., Dec 1 2019, In : Clinical Cancer Research. 25, 23, p. 6976-6985 10 p.

    Research output: Contribution to journalArticle

  • 5 Scopus citations